NASDAQ$ALHC

Alignment Healthcare Inc · Q2 2022 earnings

Q2 2022 earnings · · Investor relations

Briefing

Alignment Healthcare's second quarter showcased the replicability of their model and resulted in one of their best quarters since taking the company public.

Alignment Healthcare reported strong second-quarter results, exceeding guidance on membership, revenue, adjusted gross profit, and adjusted EBITDA. The company's medical benefits ratio was the lowest since the IPO.

  • The second quarter marks the company's lowest medical benefits ratio since the IPO.
  • The company beat guidance on four key performance indicators: membership, revenue, adjusted gross profit and adjusted EBITDA.
  • The company expects to build upon this momentum and remain confident in their team’s ability to achieve their full-year financial targets.
  • Planned 2023 market expansions are subject to regulatory approval.

Headline financials

Total Revenue

$366M

Previous: $309M+18.6%
EPS (adj)

-$0.06

Previous: -$0.25+76.0%
Free Cash Flow

-$11.6M

Previous: -$44.8M+74.1%
Net Income

-$11.6M

Previous: -$44.8M+74.1%
Operating Income

-$6.65M

Previous: -$40.5M+83.6%
Gross Profit

$366M

Previous: $309M+18.6%
Cash & Equivalents

$453M

Previous: $495M-8.4%
Total Assets

$667M

Previous: $670M-0.5%
Stock-Based Comp

$12.1M

No prior period

Revenue & EPS history

Alignment Healthcare · Revenue · Quarterly

$366M

Q2 2022+18.6%vs Q2 2021
Beat estimate in 15 of 15 quarters(100%)
ActualEstimate

Revenue by segment

Alignment Healthcare · $265M total across 2 segments · Q1 2021

  • Earned premiums
    $265M+18.0%
  • Other revenue
    $82K

Forward guidance

The company is confident in their team’s ability to achieve their full-year financial targets.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2022

Historical avgQ2 2022

+1.8%

Avg return

Earnings day

+1.8%

Avg return

5 days after

+2.6%

Avg return

30 days after

57%

12 / 21 earnings

Positive

+27.0%

Q1 2024

Best reaction

-16.4%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+3.8%-15.7%-29.5%
Q4 2025-5.8%-7.5%-18.6%
Q3 2025-1.9%-0.4%+12.2%
Q1 2025-7.7%-7.5%-8.3%
Q4 2024+16.5%+17.4%+35.9%
Q3 2024+1.6%+12.2%+11.2%
Q2 2024+2.3%+4.9%+3.1%
Q1 2024+27.0%+31.6%+51.0%
Q4 2023-8.9%-9.2%-20.1%
Q3 2023-9.6%-7.2%+10.5%
Q2 2023+7.5%+10.5%-4.2%
Q1 2023+3.5%+11.3%-5.1%
Q4 2022-16.4%-20.9%-35.2%
Q3 2022-3.1%-3.3%-2.7%
Q2 2022+10.4%+4.3%-8.7%
Q1 2022-7.0%-18.8%+6.8%
Q4 2021+10.7%+8.0%+39.7%
Q3 2021+10.6%+6.1%-26.7%
Q2 2021-8.5%-4.8%-11.2%
Q1 2021+6.8%+13.3%+27.6%
Q4 2020+6.8%+13.3%+27.6%
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro